Ignite Creation Date:
2024-05-06 @ 2:56 PM
Last Modification Date:
2024-10-26 @ 1:40 PM
Study NCT ID:
NCT04477239
Status:
COMPLETED
Last Update Posted:
2021-04-01
First Post:
2020-07-14
Brief Title:
Diagnostic Performance of Urinary Gluten Immunogenic Peptides in Monitoring the Adherence to Gluten-free Diet
Sponsor:
Università Politecnica delle Marche
Organization:
Università Politecnica delle Marche
Study Overview
Official Title:
A Randomized Triple-blind Placebo-controlled Clinical Trial on the Diagnostic Performance of Gluten Immunogenic Peptides in the Evaluation of Gluten-free Diet Adherence the GRRES Study
Status:
COMPLETED
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the GRRES study is to assess the clinical usefulness of urinary gluten immunogenic peptides test as a marker of gluten-free diet adherence using the rapid immunochromatographic assay based on anti-gliadin 33-mer monoclonal antibodies
Detailed Description:
A strict and permanent gluten free diet GFD is the only effective treatment resulting in full clinical serological and histological remission avoiding long-term complications in celiac disease CD patients Gluten immunogenic peptides GIP are fragments of gluten proteins resistant to gastrointestinal digestion and detectable in urine after intestinal digestion providing direct evidence of recent gluten ingestion A significant variability in the amount of excreted urinary GIP has been reported in individuals administered with similar doses of gluten and so far inadequate information is available about the amount of excreted GIP in subjects ingesting traces or low amount of gluten This is an important issue as even a strict GFD could be contaminated by traces of gluten eg in wheat starch and processed food The aim of this study is to assess the clinical usefulness of urinary GIP as a marker of GFD adherence using a rapid immunochromatographic assay based on anti-gliadin 33-mer monoclonal antibodies This is a prospective randomized triple-blind placebo-controlled clinical trial In this study healthy volunteers following a normal diet will be requested to be on strict GFD for 5 days On day 4th participants will be requested to collect a baseline urine sample and in case of a negative GIP test result they will be assigned to ingest a specific dose of purified gluten incorporated in a capsule 0 mg 10 mg 50 mg 100 mg 500 mg and 1000 mg according to randomization Participants will be requested to collect urine samples in a container and take a 5 mL aliquote for the GIP test at the 9th and 24th hour from the time of the administration of the dose During the collection volunteers will also be requested to record the volume of the excreted urine and to store the collected urine at 4C Urine tubes will be stored at -20C until the quantitative evaluation of GIP GIP test will be performed using the rapid immunochromatographic assay based on anti-gliadin 33-mer monoclonal antibodies iVYCHECK GIP Urine test Biomedal Spain according to the manufacturers instructions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None